Results 61 to 70 of about 10,117 (217)

Use of Allopurinol with Low-Dose 6-Mercaptopurine in Inflammatory Bowel Disease to Achieve Optimal Active Metabolite Levels: A Review of Four Cases and the Literature

Canadian Journal of Gastroenterology, 2008
BACKGROUND: At least one-third of patients with inflammatory bowel disease do not respond or are intolerant to therapy with 6-mercaptopurine (6-MP). A subgroup fails to attain optimal levels of 6-thioguanine nucleotide (6-TGN) and instead shunts to 6 ...
Todd N Witte, Allen L Ginsberg
doaj   +1 more source

The first cases of collagenous sprue successfully treated with thioguanine

BMJ Open Gastroenterology, 2016
Objective Collagenous sprue (CS) is a rare form of small bowel enteropathy characterised by a thickened basement membrane and is, in most of the literature, reported as part of coeliac disease. Multiple treatment strategies are suggested in CS, but there
Chris J J Mulder, Gerd Bouma, Tom van Gils, Tine van de Donk, Foke van Delft, E Andra Neefjes-Borst   +5 more
doaj   +1 more source

Thiopurine S-Methyltransferase Polymorphism in Iraqi Paediatric Patients with Acute Lymphoblastic Leukaemia [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: Acute Lymphoblastic Leukaemia (ALL) treatment protocols widely used thiopurine drugs as an anti-cancer agent, which over the course of time results in drug toxicity.
NAWARS MOHAMMED, MANALK RASHEED, HASANEIN H GHALI   +2 more
doaj   +1 more source

Transgenic selection and underlying mechanisms in apicomplexan parasites

The FEBS Journal, EarlyView.
Transgenic selection markers have driven genetic engineering in apicomplexans, enabling precise, iterative experiments. This review discusses mechanistic details of drug selection markers, strategies for marker recycling, and practical considerations for several clinically relevant parasites.
Swaroop Peddiraju, Rakhee Lohia, Nishith Gupta   +2 more
wiley   +1 more source

Evaluation the antibacterial efficacy of thioguanine

, 2023
This study has revealed the effect of thioguanine as an antimicrobial agent, and has shown that that thio-purine derivative enhanced might be able to combat infections caused by some bacteria strains in the ...
Sysa, A., Albasri, S.
core  

Human APOBEC3G suppresses homologous recombination and LIG4‐independent end joining in DNA double‐strand break repair

The FEBS Journal, EarlyView.
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito, Miori Murayama, Usaki Arai, Sekifumi Akatsu, Ami Yamamoto, Misaki Kadoguchi, Noritaka Adachi   +6 more
wiley   +1 more source

Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine Some evidence for dose or metabolite level dependent effects?

, 2007
BACKGROUND: 6-Thioguanine is used in inflammatory bowel disease since 2001, with promising short-term results. In 2003, liver histology of some 6-thioguanine treated patients showed nodular regenerative hyperplasia.
Engels, L.G.B., Derijks, L.J., Driessen, A., Hooymans, P.M., Bos, L.P., Gilissen, L.P., Stockbrugger, R.W.   +6 more
core   +1 more source

Molecular Modelling of Optical Biosensor Phosphorene-Thioguanine for Optimal Drug Delivery in Leukemia Treatment

, 2022
Thioguanine is an anti-cancer drug used for the treatment of leukemia. However, thioguanine has weak aqueous solubility and low biocompatibility, which limits its performance in the treatment of cancer.
Akbar Hussain, Shabeer Ahmad Mian, Joonkyung Jang, Shafqat Ullah Khan, Abdur Rauf, Ejaz Ahmed   +5 more
core   +1 more source

EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES

Mediterranean Journal of Hematology and Infectious Diseases, 2011
Of 1614 Nordic children with ALL that were treated according to the NOPHO ALL92 protocol, 20 developed an SMN (cumulative risk at 12 years: 1.6%). Sixteen of the twenty SMNs were acute myeloid leukemias or myelodysplasias, and 9 of these had either ...
Kjeld Schmiegelow
doaj   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source